Text Size

Prophylactic Antibiotic Treatment During Vaginal Repair

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2005 by Hvidovre University Hospital.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Hvidovre University Hospital
ClinicalTrials.gov Identifier:
NCT00162604
First received: September 9, 2005
Last updated: September 8, 2006
Last verified: February 2005
History of Changes
  Purpose

Prolapse of the uterus, bladder and rectum is a common condition in multiparous and/or elderly women. The number of operations for vaginal repair is increasing in Denmark, but there is no consensus or evidence found about the efficiency of prophylactic antibiotics intraoperatively concerning postoperative infections.

The objective of this randomized, controlled trial is to investigate the significance of prophylactic antibiotic treatment in vaginal repair operations.


Condition Intervention
Uterine Prolapse
Cystocele
Rectocele
Enterocele
 Drug: Cefuroxime

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Prevention
Official Title: Antibiotikaprofylakse Ved Vaginalplastik

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Hvidovre University Hospital:

Primary Outcome Measures:
  • primary endpoint: no infections (urinary tract infections, pneumonia,wound infections, infected haematomas, etc.) within 30 days postoperatively

Estimated Enrollment: 200
Study Start Date: May 2005
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Women ages 18+ with uterine prolapse grade I - II and/or cystocele and/or rectocele and/or enterocele grade I - II and/or defects of the perineal body, in whom there is medical indication for vaginal repair, but no indication for vaginal hysterectomy or transvaginal suspension of the vaginal vault after prior hysterectomy.

Exclusion Criteria:

  • Patients allergic to cefuroxime.
  • Patients in whom a vaginal hysterectomy or a transvaginal suspension of the vaginal vault or other major surgery is planned, where prophylactic antibiotic treatment is standard.
  • Patients suffering from physical or mental disorders that will not allow them to give informed consent.
  • Pregnant and nursing women.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00162604

Contacts
Contact: Marianne Ottesen, M.D 0045 36323632 ext 3540 marianne.8sen@dadlnet.dk

Locations
Denmark
Hvidovre University Hospital Recruiting
Hvidovre, Denmark, 2650
Contact: Marianne Ottesen, M.D     0045 36323632 ext 3540     marianne.8sen@dadlnet.dk    
Sub-Investigator: Tina Olsen, M.D            
Sub-Investigator: Abelone Elisabeth Sakse, M.D            
Principal Investigator: Marianne Ottesen, M.D, PhD            
Sponsors and Collaborators
Hvidovre University Hospital
Investigators
Study Director: Marianne Ottesen, M.D, Ph.D Hvidovre University Hospital
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00162604     History of Changes
Other Study ID Numbers: 2602-415
Study First Received: September 9, 2005
Last Updated: September 8, 2006
Health Authority: Denmark: Danish Medicines Agency

Keywords provided by Hvidovre University Hospital:
Prophylactic antibiotic
Postoperative infections
Uterine prolapse grade I - II
cystocele
 rectocele
enterocele
defects of the perineal body

Additional relevant MeSH terms:
Cystocele
Prolapse
Uterine Prolapse
Rectocele
Hernia
Urinary Bladder Diseases
Urologic Diseases
Pelvic Organ Prolapse
Pathological Conditions, Anatomical
Uterine Diseases
Genital Diseases, Female
 Rectal Diseases
Intestinal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Anti-Bacterial Agents
Cefuroxime
Cefuroxime axetil
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on May 16, 2013